The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current findings include targeted therapies for tumors with PIK3CA and FGFR mutations, a promising combination therapy for myelofibrosis, a new target to improve immunotherapy response in pancreatic cancer, a novel method of increasing...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting...
The University of Texas MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of Texas (CPRIT...
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner MD Anderson Cancer Center in 2011. The renewed agreement extends the relationship for an additional 10 years.
Banner MD Anderson is a comprehensive and clinically integrated cancer care program and was the first partner to join MD Anderson Cancer Network®, a global network of hospitals and...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...